HGH Fragment 176-191 (lipolytic)

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

12 hours

Absorption half-life assumed

3 hours

Reference amount for the relative scale

1 mg

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product identity, free-base/salt basis and route must be specified before absolute calibration. The stored 12-hour timing is unsupported, not a source-backed elimination half-life.

• FDA AOD-9604 briefing, December2024

  Defines AOD-9604 as Tyr-hGH177–191; clinical PK section reports no identified human PK/PD studies. Nonclinical exposure findings cannot validate a generic human SC curve.

hgh-frag-176-191-relative-timing-2026-10 · version 1